Paternity, relationship, sexual activity and fertility in testicular cancer (TC) survivors (TCS): Results from a single institution observational prospective study.

Authors

null

Davide Bimbatti

Medical Oncology Unit 1, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS, Padua, Italy

Davide Bimbatti , Francesco Pierantoni , Marco Maruzzo , Filippo Maria Deppieri , Aichi Msaki , Maura Gatti , Michele Dionese , Eleonora Lai , Dario Marino , Umberto Basso , Vittorina Zagonel

Organizations

Medical Oncology Unit 1, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS, Padua, Italy

Research Funding

No funding received
None.

Background: TC represents 1% of male neoplasms but it is the most common in young adults. Interdisciplinary management with chemotherapy, radiotherapy and surgery has led to a 10-year relative survival rate of up to 95%. These treatments (Tx) have short- and long-term side effects. While sexual dysfunction can reduce fertility, psychosocial distress can create relationship problems and finally affect the ability to procreate. Methods: From February 2020, we submitted a series of questionnaires to all the patients (pts) currently followed-up at the Istituto Oncologico Veneto free from TC recurrence for at least 2 years from the last Tx. International Index of Erectile Function (IIEF-15) and Premature Ejaculation Diagnostic Tool (PEDT) were used. We also set up a questionnaire to investigate paternity and family status. Data about disease and treatments were collected from medical records. Results: 84 TCS completed the questionnaires, clinical data are reported in the table below. 29,8% of pts fathered children before diagnosis with a strong correlation with older age at diagnosis (45,4 vs 30,8 years, p<0,001). After Tx, 14 pts had children: 9 of which naturally, 2 out 6 were successful via assisted reproductive technology (ART) (including one patient that received high-dose chemotherapy and stem cell transplantation), 3 via adoption. 89,3% of pts had stable relationships. Of pts who did not have children: 13,1% claimed to be due to lack of a partner, 39,3% claimed to be unready, while 14,3% had tried unsuccessfully to conceive. While 28,6% pts claim to currently have fertility issues, only 8,3% of pts reported to have these issues before diagnosis. 70,2% of pts performed a spermiogram after Tx, 10 pts had spermatogenic impairment. Higher rate of sexual dysfunction after Tx was detected by questionnaires while only 4 pts claimed to have had a pre-existing issue prior to TC diagnosis. PEDT shows that 38,1% had premature ejaculation and that in 22,6% this issue is highly probable. IIEF confirms a high rate of erectile dysfunction (14,3% severe and 10,7% mild or moderate). No correlations were identified between sexual dysfuntion and previous Tx. Conclusions: Most TCS had not planned fatherhood while 16,7% had children after Tx and 14.3% tried unsuccessfully to conceive. ART and adoption is possible but challenging and little used. PEDT and IIEF found high rates of sexual dysfunction but no association with previous Tx were found.

Median age at diagnosis33,5 years
Median current age40,5 years
Median time elapsed from diagnosis5 years
Istology:Seminoma/Non Seminoma59,5%/40,5%
Stage:Localized/Lymph Nodes/Advanced63,1%/8,3%/28,6%
Tx: Adjuvant chemo/3-4 BEP/RPLND/radiotherapy/At least 2 Tx42,9%/41,7%/10,7%/4,8%/17,9%

BEP=bleomycin etoposide cisplatin; RPLND=retroperitoneal lymph node dissection.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2021 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session: Adrenal, Penile, Testicular, and Urethral Cancers

Track

Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer

Sub Track

Patient-Reported Outcomes and Real-World Evidence

Citation

J Clin Oncol 39, 2021 (suppl 6; abstr 380)

DOI

10.1200/JCO.2021.39.6_suppl.380

Abstract #

380

Poster Bd #

Online Only

Abstract Disclosures

Similar Abstracts

Abstract

2024 ASCO Genitourinary Cancers Symposium

Longitudinal assessment of cognitive functioning in testicular germ cell tumor survivors.

First Author: Zuzana Orszaghova

First Author: Marcin W Wojewodzic

Abstract

2023 ASCO Genitourinary Cancers Symposium

Peripheral blood immune cell profiling in survivors of testicular germ cell tumors.

First Author: Michal Chovanec

Abstract

2023 ASCO Genitourinary Cancers Symposium

Impact of chemotherapy on anxiety, depression, and suicidality amongst testicular cancer survivors.

First Author: Tyler J. Nelson